EGFL7 Antibody / EGF-like domain-containing protein 7 [clone EGFL7/9497] (V5965)

Catalog No.	Formulation	Size
V5965-100UG	0.2 mg/ml in 1X PBS with 0.05% BSA, 0.05% sodium azide	100 ug
V5965-20UG	0.2 mg/ml in 1X PBS with 0.05% BSA, 0.05% sodium azide	20 ug
V5965SAF-100UG	1 mg/ml in 1X PBS; BSA free, sodium azide free	100 ug

Bulk quote request

Species Reactivity	Human
Format	Purified
Host	Mouse
Clonality	Monoclonal (mouse origin)
Isotype	Mouse IgG1, kappa
Clone Name	EGFL7/9497
UniProt	Q9UHF1
Localization	Extracellular space, Secreted
Applications	Immunohistochemistry (FFPE) : 1-2ug/ml Western Blot : 2-4ug/ml
Limitations	This EGFL7/EGF-like domain-containing protein 7 antibody is available for research use only.



Immunohistochemistry analysis of EGFL7 / EGF-like domain-containing protein 7 antibody in human tonsil. FFPE human tonsil tissue was stained with EGFL7 / EGF-like domain-containing protein 7 antibody (clone EGFL7/9497). HRP-DAB brown chromogenic signal is observed predominantly along the endothelial lining of vascular structures and within the extracellular matrix surrounding vessels, consistent with the known extracellular and endothelial-associated localization of EGFL7. Vascular endothelial cells display membranous and cytoplasmic brown staining, while adjacent lymphoid cells show minimal background signal. Nuclei are counterstained blue. The inset image shows PBS used instead of primary antibody, demonstrating absence of specific HRP-DAB brown staining and confirming staining specificity. Heat-induced epitope retrieval was performed in 10 mM Tris with 1 mM EDTA, pH 9.0, for 45 minutes at 95oC followed by cooling at room temperature for 20 minutes prior to antibody incubation.



Western blot analysis of EGFL7 / EGF-like domain-containing protein 7 antibody in human tissues and cell lines. Western blot was performed using EGFL7 / EGF-like domain-containing protein 7 antibody (clone EGFL7/9497) on human kidney, human lung, human spleen, HL60, K-562, and MCF7 lysates. A distinct immunoreactive band is detected at approximately 27 kDa across the tested samples, consistent with the predicted molecular weight of EGFL7. Band intensity varies among tissues and cell lines, reflecting differential expression of EGFL7 in vascularized tissues and proliferative cell populations. The detected signal corresponds to the predicted molecular weight under reducing conditions. EGFL7 is a secreted extracellular matrix-associated protein primarily expressed by endothelial cells, and its detection in these lysates supports specific recognition of endogenous EGFL7.



Western blot analysis of EGFL7 / EGF-like domain-containing protein 7 antibody in human 293T cell lysate. A distinct immunoreactive band is detected at approximately 27 kDa, consistent with the predicted molecular weight of EGFL7.



SDS-PAGE Analysis Purified EGFL7/EGF-like domain-containing protein 7 antibody (EGFL7/9497). Confirmation of Purity and Integrity of Antibody.

Description

EGFL7 antibody, also known as EGF-like domain-containing protein 7 antibody, recognizes a secreted extracellular matrix-associated protein commonly referred to as Epidermal growth factor-like protein 7 and Vascular endothelial statin. EGF-like domain-containing protein 7 is encoded by the EGFL7 gene located on chromosome 9q34 and is predominantly expressed by endothelial cells. The protein is secreted into the extracellular space, where it associates with the vascular basement membrane and plays an important role in angiogenesis and vascular development. EGFL7 expression is particularly prominent during embryogenesis and in actively remodeling vasculature.

EGF-like domain-containing protein 7 functions as a regulator of endothelial cell adhesion, migration, and tubulogenesis. It contributes to vascular lumen formation and maintains endothelial integrity by modulating interactions between endothelial cells and the extracellular matrix. EGFL7 antibody is commonly used in studies investigating angiogenesis, vascular morphogenesis, and tumor-associated neovascularization. The protein is also implicated in Notch signaling modulation, influencing endothelial differentiation and vascular patterning.

Structurally, EGF-like domain-containing protein 7 contains multiple epidermal growth factor-like repeats that mediate protein-protein interactions within the extracellular matrix. Through these domains, EGFL7 interacts with integrins and other matrix components to regulate endothelial cell behavior. Its expression is tightly controlled during development, with high levels observed in embryonic vasculature and reduced expression in most normal adult tissues, except in sites of active vascular remodeling or repair.

Dysregulated EGFL7 expression has been associated with tumor progression and metastasis. Elevated levels are observed in various cancers, including colorectal, breast, and hepatocellular carcinoma, where increased vascularization supports tumor growth. Because EGFL7 is largely endothelial-specific, it serves as a useful marker for studying tumor

vasculature and angiogenic processes. Its extracellular localization also makes it of interest in therapeutic targeting strategies aimed at modulating angiogenesis.

EGFL7 antibody supports research into vascular biology, developmental angiogenesis, and tumor microenvironment signaling. Clone EGFL7/9497 recognizes EGF-like domain-containing protein 7 and is suitable for detecting EGFL7 expression in relevant research applications.

Application Notes

Optimal dilution of the EGFL7/EGF-like domain-containing protein 7 antibody should be determined by the researcher.

Immunogen

A recombinant fragment (around amino acids 1-200) of human EGFL7 protein (exact sequence is proprietary) was used as the immuongen for the EGFL7/EGF-like domain-containing protein 7 antibody.

Storage

EGFL7/EGF-like domain-containing protein 7 antibody with sodium azide - store at 2 to 8oC; antibody without sodium azide - store at -20 to -80oC.